Who are low molecule heparin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, Coumadin, Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container, Heparin Sodium In Plastic Container.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-molecule-heparin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

low molecule heparin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

low molecule heparin (low molecule heparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

marketed Anticoagulant Antithrombin III (indirect); Factor Xa and Factor IIa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

low molecule heparin (low molecule heparin) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
low molecule heparin TARGET	low molecule heparin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Anticoagulant	Antithrombin III (indirect); Factor Xa and Factor IIa
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

Fresenius Kabi · 4 drugs in this class
University of Sao Paulo · 3 drugs in this class
Beijing Anzhen Hospital · 2 drugs in this class
San Filippo Neri General Hospital · 2 drugs in this class
Yong Seog Oh · 2 drugs in this class
CCRF Consulting Co., Ltd. · 1 drug in this class
Boston Scientific Corporation · 1 drug in this class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
Faculty Hospital Kralovske Vinohrady · 1 drug in this class
Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low molecule heparin — Competitive Intelligence Brief. https://druglandscape.com/ci/low-molecule-heparin. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing